These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1147055)

  • 1. Use of diphenylhydantoin and diazoxide to investigate insulin secretory mechanisms.
    Levin SR; Charles MA; O'connor M; Grodsky GM
    Am J Physiol; 1975 Jul; 229(1):49-54. PubMed ID: 1147055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the inhibitory effects of diphenylhydantoin and diazoxide upon insulin secretion from the isolated perfused pancreas.
    Levin SR; Grodsky GM; Hagura R; Smith D
    Diabetes; 1972 Aug; 21(8):856-62. PubMed ID: 4558084
    [No Abstract]   [Full Text] [Related]  

  • 3. Diphenylhydantoin suppresses glucose-induced insulin release by decreasing cytoplasmic H+ concentration in pancreatic islets.
    Nabe K; Fujimoto S; Shimodahira M; Kominato R; Nishi Y; Funakoshi S; Mukai E; Yamada Y; Seino Y; Inagaki N
    Endocrinology; 2006 Jun; 147(6):2717-27. PubMed ID: 16527842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diazoxide effects on biphasic insulin release: "adrenergic" suppression and enhancement in the perifused rat pancreas.
    Burr IM; Marliss EB; Stauffacher W; Renold AE
    J Clin Invest; 1971 Jul; 50(7):1444-50. PubMed ID: 5090060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic effects of diazoxide and diphenylhydantoin on insulin secretion and biosynthesis in B cells of mice.
    Bommer G; Schäfer HJ; Klöppel G
    Virchows Arch A Pathol Anat Histol; 1976 Sep; 371(3):227-41. PubMed ID: 823696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in vitro inhibition of insulin secretion by diphenylhydantoin.
    Kizer JS; Vargas-Gordon M; Brendel K; Bressler R
    J Clin Invest; 1970 Oct; 49(10):1942-8. PubMed ID: 4918328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin secretion studied in the perfused rat pancreas. I. Effect of tolbutamide, leucine and arginine; their interaction with diazoxide, and relation to glucose.
    Basabe JC; Lopez NL; Viktora JK; Wolff FW
    Diabetes; 1971 Jul; 20(7):449-56. PubMed ID: 5556282
    [No Abstract]   [Full Text] [Related]  

  • 8. Glucagon is paradoxically secreted at high concentrations of glucose in rat pancreas perfused with diazoxide.
    Mokuda O; Shibata M; Ooka H; Okazaki R; Sakamoto Y
    Diabetes Nutr Metab; 2002 Aug; 15(4):260-4. PubMed ID: 12416665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of insulin release by diphenylhydantoin and diazoxide in a patient with benign insulinoma.
    Cohen MS; Bower RH; Fidler SM; Johnsonbaugh RE; Sode J
    Lancet; 1973 Jan; 1(7793):40-1. PubMed ID: 4118560
    [No Abstract]   [Full Text] [Related]  

  • 10. [Modification of insulin-secretion, induced by glucose, of the isolation-perfused rat pancreas using tolbutamide, glucosamine, diazoxide, glucagon and endogenous insulin].
    Bierwolf B; Blech W
    Acta Biol Med Ger; 1976; 35(5):583-95. PubMed ID: 983609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin secretion studied in the perfused rat pancreas. II. Effect of glucose, glucagon, 3'5' adenosine monophosphate, theophylline, imidazole and phenoxybenzamine; their interaction with diazoxide.
    Basabe JC; Lopez NL; Viktora JK; Wolff FW
    Diabetes; 1971 Jul; 20(7):457-66. PubMed ID: 4397560
    [No Abstract]   [Full Text] [Related]  

  • 12. B-cell insensitivity in vitro: reversal by diazoxide entails more than one event in stimulus-secretion coupling.
    Björklund A; Grill V
    Endocrinology; 1993 Mar; 132(3):1319-28. PubMed ID: 7679978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The action of sulfonylureas on the insulin secretion of the perfused rat pancreas].
    Mariani MM
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():256-70. PubMed ID: 5371307
    [No Abstract]   [Full Text] [Related]  

  • 14. Attenuated anomeric difference of glucose-induced insulin release in the perfused pancreas of diazoxide-treated rats.
    Leclercq-Meyer V; Marchand J; Malaisse WJ
    Horm Metab Res; 1991 Jun; 23(6):257-61. PubMed ID: 1916634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.
    Blayac JP; Ribes G; Buys D; Puech R; Loubatieres-Mariani MM
    Arch Int Pharmacodyn Ther; 1981 Sep; 253(1):154-63. PubMed ID: 6119962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of glucagon secretion by diazoxide in vitro.
    Urdanivia E; Pek S; Santiago JC
    Diabetes; 1979 Jan; 28(1):26-31. PubMed ID: 759248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic, cationic and secretory response to D-glucose in depolarized and Ca(2+)-deprived rat islets exposed to diazoxide.
    Lebrun P; Antoine MH; Nguyen QA; Picton S; Malaisse WJ
    Cell Calcium; 2000 Apr; 27(4):213-22. PubMed ID: 10858667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro effects of ethanolamine on insulin secretion.
    Barseghian G; Zak I; Hwang DL; Roitman A; Lev-Ran A
    Life Sci; 1986 Feb; 38(7):645-51. PubMed ID: 3511347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent pharmacologic aspects of sulfamides modifying insulin secretion (hypoglycemic and hyperglycemic sulfamides)].
    Loubatiéres A; Mariani MM
    Actual Physiol Pathol (Paris); 1973; 4():237-66. PubMed ID: 4219256
    [No Abstract]   [Full Text] [Related]  

  • 20. Biphasic insulin release as the expression of combined inhibitory and potentiating effects of glucose.
    Nesher R; Cerasi E
    Endocrinology; 1987 Sep; 121(3):1017-24. PubMed ID: 3304974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.